Campone M et al. Cardiac dysfunction induced by trastuzumab. Bull Cancer 2004;91(Suppl 3):166-73. Abstract

Cvetkovic RS, Scott LJ. Dexrazoxane: A review of its use for cardioprotection during anthracycline chemotherapy. Drugs 2005;65(7):1005-24. Abstract

Ewer MS et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23(31):7820-6. Abstract

Gelber RD for the HERA Study Team. Trastuzumab following adjuvant chemotherapy significantly improves disease-free survival in HER2-positive early breast cancer. The HERA trial. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 11.

Kim C et al. Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo. San Antonio Breast Cancer Symposium 2005;Abstract 46.

Mrozek E et al. Phase I trial of liposomal encapsulated doxorubicin (Myocet; D-99) and weekly docetaxel in advanced breast cancer patients. Ann Oncol 2005;16(7):1087-93. Abstract

Perez EA et al. NCCTG N9831: May 2005 update. Presentation. ASCO 2005;Abstract 556.

Piccart-Gebhart MJ et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72. Abstract

Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER 2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract

Tan-Chiu E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23(31):7811-9. Abstract

Tripathy D et al. Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2004;5(4):293-8. Abstract